martes, 24 de septiembre de 2024

GX-188E DNA vaccine plus pembrolizumab in HPV 16- and/or 18-positive recurrent or advance cervical cancer: a phase 2 trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00295-5/fulltext?dgcid=hubspot_update_feature_updatealerts_eclinm&utm_campaign=update-eclinm&utm_medium=email&_hsenc=p2ANqtz-83lEdeUKcr-JaNrAx4hWdIlGV3j4NUspZILdVNbEtibhJ_us74tfAY9u8YKk9Sr16QRM8SSXvebtUJjZLZ2Fhx9zw0ng&_hsmi=325242904&utm_content=325199816&utm_source=hs_email

No hay comentarios:

Publicar un comentario